Hypertension Clinical Trials in Barcelona
18 recruitingBarcelona, Spain
Showing 1–18 of 18 trials
Recruiting
Not Applicable
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
HypertensionHypertension, SystolicHypertension,Essential
Orchestra BioMed, Inc500 enrolled98 locationsNCT06059638
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Phase 3
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Hypertension
Eli Lilly and Company974 enrolled101 locationsNCT06948422
Recruiting
Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled63 locationsNCT07218029
Recruiting
Phase 2
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Hypertension, Pulmonary
Merck Sharp & Dohme LLC130 enrolled55 locationsNCT06814145
Recruiting
Phase 1Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals232 enrolled29 locationsNCT06649110
Recruiting
Phase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC42 enrolled35 locationsNCT05587712
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Hypertension
Eli Lilly and Company487 enrolled99 locationsNCT06952530
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionOverweight or Obesity
Eli Lilly and Company487 enrolled99 locationsNCT06948435
Recruiting
Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Interstitial Lung DiseasePulmonary Hypertension
Insmed Incorporated344 enrolled30 locationsNCT07179380
Recruiting
Phase 2
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction
Tectonic Therapeutic180 enrolled86 locationsNCT06616974
Recruiting
Not Applicable
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)
Pulmonary Hypertension
Gradient Denervation Technologies20 enrolled3 locationsNCT06495970
Recruiting
Not Applicable
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
PreeclampsiaIntrauterine Growth RestrictionMaternal Hypertension+2 more
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau9,132 enrolled21 locationsNCT04766866
Recruiting
Phase 3
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Hepatocellular CarcinomaAdvanced Chronic Liver DiseasePortal Hypertension
Hospital Universitari Vall d'Hebron Research Institute300 enrolled1 locationNCT06434753
Recruiting
Not Applicable
Urban-training Intervention in Pulmonary Hypertension (UTHAP)
Pulmonary Hypertension
Hospital Clinic of Barcelona80 enrolled1 locationNCT05523557
Recruiting
Phase 4
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Pulmonary Arterial Hypertension
AOP Orphan Pharmaceuticals AG110 enrolled19 locationsNCT06317805
Recruiting
The European NAFLD Registry
Hepatocellular CarcinomaObesityCardiovascular Diseases+9 more
Newcastle University10,000 enrolled37 locationsNCT04442334